133851-67-9

Basic information

• Product Name: 1-[(4-Nitrophenyl)Methyl]pyrrolidine
• Synonyms: 1-[(4-Nitrophenyl)Methyl]pyrrolidine;1-(4-Nitrobenzyl)pyrrolidine
• CAS NO: 133851-67-9
• Molecular Formula: C₁₁H₁₄N₂O₂
• Molecular Weight: 206.244
• Mol File: 133851-67-9.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-[(4-Nitrophenyl)Methyl]pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(4-Nitrophenyl)Methyl]pyrrolidine(133851-67-9)
• EPA Substance Registry System: 1-[(4-Nitrophenyl)Methyl]pyrrolidine(133851-67-9)

Safety Data

• Hazardous Substances Data: 133851-67-9(Hazardous Substances Data)

Usage

General Description

1-[(4-Nitrophenyl)Methyl]pyrrolidine is a chemical compound that consists of a pyrrolidine ring with a 4-nitrophenylmethyl group attached to it. It is a nitro compound, which means it contains a nitro functional group that consists of a nitrogen atom bonded to an oxygen atom by a double bond. 1-[(4-Nitrophenyl)Methyl]pyrrolidine is commonly used as a reagent in organic chemistry reactions due to its ability to act as a nucleophile in the presence of a strong base. It is also used in the synthesis of various pharmaceuticals and agrochemicals. Additionally, it has been studied for its potential as a catalyst in organic reactions. However, it should be handled with care as it is known to be toxic and may cause skin and eye irritation upon contact.

Upstream product

• 123-75-1 pyrrolidine 
• 100-14-1 4-nitrobenzyl chloride 
• 1125-99-1 1-(1-Cyclohexen-1-yl)pyrrolidine 
• 53578-11-3 (4-nitrophenyl)(pyrrolidin-1-yl)methanone 
• 62-23-7 4-nitro-benzoic acid 
• 619-73-8 4-nitrobenzyl chloride 
• 609-36-9 rac-Pro-OH 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Downstream Products

• 72219-19-3 4-((pyrrolidin-1-yl)methyl)phenol 
• 142335-65-7 2-(4-Pyrrolidin-1-ylmethyl-phenoxy)-propionic acid ethyl ester 
• 1567327-16-5 5,6-dimethoxy-2-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[d][1,2]selenazol-3(2H)-one 
• 1234202-05-1 N-(2-(1H-indol-3-yl)ethyl)-4-(pyrrolidin-1-ylmethyl)aniline 
• 1234201-99-0 3-(1H-indol-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)phenyl)propanamide 
• 878106-29-7 2-(1H-indol-3-yl)-N-(4-(pyrrolidin-1-ylmethyl)phenyl)acetamide 
• 1335121-34-0 N-(4-(pyrrolidin-1-ylmethyl)phenyl)-3-(3-(trifluoromethyl)phenyl)-3H-imidazo[4,5-b]pyridine-5-carboxamide 
• 866956-98-1 [4-(pyrrolidin-1-ylmethyl)phenyl]amine hydrochloride 
• 107484-31-1 1-(4-nitrobenzyl)-1H-pyrrole 
• 142335-64-6 4-(pyrrolidin-1-ylmethyl)aniline 

Relevant articles and documents

Optical control of muscular nicotinic channels with azocuroniums, photoswitchable azobenzenes bearing two N-methyl-N-carbocyclic quaternary ammonium groups

By linking two N-methyl-N-carbocyclic quaternary ammonium groups to an azobenzene scaffold in meta- or para-positions we generated a series of photoswitchable neuromuscular ligands for which we coined the term “azocuroniums”. These compounds switched betw

A practical catalytic reductive amination of carboxylic acids

We report reductive alkylation reactions of amines using carboxylic acids as nominal electrophiles. The two-step reaction exploits the dual reactivity of phenylsilane and involves a silane-mediated amidation followed by a Zn(OAc)2-catalyzed amide reduction. The reaction is applicable to a wide range of amines and carboxylic acids and has been demonstrated on a large scale (305 mmol of amine). The rate differential between the reduction of tertiary and secondary amide intermediates is exemplified in a convergent synthesis of the antiretroviral medicine maraviroc. Mechanistic studies demonstrate that a residual 0.5 equivalents of carboxylic acid from the amidation step is responsible for the generation of silane reductants with augmented reactivity, which allow secondary amides, previously unreactive in zinc/phenylsilane systems, to be reduced.

Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent

Many people are affected by Malaria around the world, and the parasite is developing resistance against available drugs. Currently, isoquine and N-tert-butyl isoquine are some of the most promising antimalarial candidates that have already reached Phase I